In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated partial thromboplastin time, which currently allow only a screening for increased risk for bleeding but not for venous thromboembolism. A new functional screening test for the protein C system such as the presented ProC ® Global should therefore facilitate detection of FV Leiden as well as deficiency of protein C and protein S. The results of the present evaluation indicate that ProC Global is highly sensitive to activated protein C resistance/FV Leiden (100%) and protein C deficiency (90%) and sensitive to protein S deficiency (63%). Furthermore, the assay gives a quantitative measure of the net potential of the protein C pathway in relation to the intrinsic procoagulant system. The use of this assay for a prospective assessment of thromboembolic risk is the subject of current studies.
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Thrombophilia due to a defect within the protein C pathway is a major hereditary cause of venous thromboembolic disease. Besides the coagulation factor V (FV) Leiden mutation, which can be detected in 20 -40% of patients presenting with thromboembolic disease [1] [2] [3] , deficiencies of protein C and protein S, with a prevalence of 2-4% in symptomatic patients, are the most frequent hereditary abnormalities associated with thrombophilia [1, 4] . 3 Thus, in total, between 25% and 50% of thrombotic patients have a decreased functionality of their protein C anticoagulant pathway. However, thrombophilia can result from inherited and acquired defects within the coagulation system [5] , which may be caused by a decreased activity of the anticoagulant system as well as by an increased activity of the procoagulant system. Nevertheless, both alterations induce a shift in the hemostatic balance toward an increased tendency for venous thromboembolism.
In the present study, a recently described new screening assay for defects within the protein C system-ProC ® Global-was evaluated in the clinical routine with special regard to the establishment of its sensitivity for FV Leiden, as well as for a deficiency for protein C and protein S [6] .
Materials and Methods
ProC Global assay. ProC Global (Behring Diagnostics) is an activated partial thromboplastin time (APTT)-based assay in which Protac ® (snake venom from Agkistrodon contortrix, Pentapharm) is used for activation of the endogenous protein C of the plasma sample (see Fig. 1 ). The protein C activation time (PCAT) in presence of the activator is set in relation to a parallel determination of the PCAT/0 with addition of a buffer instead of activator reagent. The pipetting scheme is as follows: For PCAT, add 50 L of activator reagent and 50 L of APTT reagent (Pathromtin SL) to 50 L of a citrated plasma sample; for PCAT/0, add 50 L of buffer and 50 L of APTT reagent to 50 L of a citrated plasma sample. Incubate both for 3 min at 37°C. Then to both add 50 L of CaCl 2 start reagent, and measure the clotting time.
To obtain a better comparability of results and to exclude influences of instrumentation and of reagent lot, the ratios PCAT:PCAT/0 are transformed in normalized ratios (NR) by relating them to a precalibrated calibrator.
NR ϭ ratio of sample ϫ sensitivity value calibrator/ ratio of calibrator.
Citrated plasma samples can be applied either fresh (within 4 h after blood collection) or after freezing (Ϫ20°C). As for all coagulation tests, careful blood collection and processing is a prerequisite for reliable results. If samples are frozen, care has to be taken to prepare platelet-poor plasma, as activated platelets may cause a shortening of clotting time.
Two quality-control plasmas (Control Plasma N for the normal range and ProC Control Plasma for the pathological range, Behring Diagnostics) were assayed in each run. The run was only considered valid if results of both controls were within the confidence range.
Heparin concentrations up to 1000 U/L do not produce interference with the assay system because the buffer and activator reagent contain a heparin inhibitor, allowing thrombophilia screening under heparin therapy. However, any deficiencies of procoagulant factors will prolong both PCAT and PCAT/0. Whether the system still works in the case of severe deficiencies could not be proved. Therefore, for guaranteeing the validity of assay results, a limit of the PCAT/0 of 60 s was established to ensure a baseline activity of the procoagulant system. Samples from patients under oral anticoagulant therapy should not be used in the ProC Global assay, as the severe reduction of protein C activity due to vitamin K absence does not allow the determination of a possible preexisting defect before therapy. In response to vitamin K antagonist therapy, ProC Global NRs generally decline with increasing intensity of therapy [7] . To avoid influences and misinterpretation of results due to oral anticoagulation, only samples with a prothrombin time (PT) within the normal range were included in this study.
Plasma samples and measured parameters. From citrated blood samples submitted for a routine thrombophilia screening, platelet-poor plasma was prepared by double centrifugation and stored frozen at Ϫ20°C. ProC Global assay was performed on the Behring Coagulation Timer (Behring Diagnostics). In addition to ProC Global, samples were assayed for FV Leiden (Coatest APC Resistence, Chromogenics, 1ϩ4 dilution of samples in FV-deficient plasma), protein C activity (chromogenic assay, Boehringer Mannheim), and protein S activity (clotting test, Boehringer Mannheim).
Results
From the data obtained, patients were divided into four groups:
1) FV Leiden/activated protein C (APC) resistance: all samples with an APC/FV ratio Ͻ2.0, irrespective of showing an additional protein C or protein S deficiency.
2) Protein C deficiency: samples with protein C activity Ͻ70%, irrespective of their protein S activity.
3) Protein S deficiency: samples with protein S activity Ͻ60%.
4) Patients without defects in the protein C system: all residual samples.
For comparison purposes, also data from a reference range study performed by the manufacturer are shown. By testing 70 healthy blood donors (FV Leiden carriers were excluded), a range of 0.77 to 1.80 NR (median 1.05 NR) was observed. In comparison, in patients with FV Leiden defect as well as with reduced protein C and protein S activity, significantly lower median NRs (0.49, 0.68, and 0.77, respectively) were obtained in the ProC Global assay (Table 1 ). However, in the patient group without a detectable defect within the protein C system, ProC Global results were significantly lower (median 0.85 NR) when compared with healthy donors. On the other side, the results were considerably higher than for patients with a proven defect in the protein C system. All samples expected to be positive for the FV Leiden mutation because of their abnormal result in the APC resistance test (with predilution in FV-deficient plasma) were abnormal within ProC Global (below the proposed cutoff of 0.8 NR; see Fig. 2 ). This was the case also in 90% of the samples with protein C Ͻ70%, whereas protein S-deficient samples (activity Ͻ60%) were only abnormal in 63%.
The three protein C-deficient samples with ProC Global results above the cutoff had a mean protein C activity of 62.7% (range 58 -69%); the mean protein S activity of the seven protein S-deficient samples with a normal ProC Global result was 49.7% (range 35-58%).
Of patients without FV Leiden or deficiency of protein C or protein S, 38% showed abnormal results, in contrast to a rate of only 5% abnormal results in healthy blood donors. Since for all patients included in this study "thrombophilia" tests had been requested, most of them could be expected to be afflicted by thrombophilia or to be in a high-risk situation. Furthermore, in most patients, signs of an acute-phase reaction were present, e.g., increased concentration of fibrinogen as well as increased concentrations of FVIII, which could explain a shift of the hemostatic balance to hypercoagulability and thrombophilia as a cause of an increased activity of the procoagulant system. Thus, the higher rate of abnormal results in thrombophilic patients compared with healthy individuals is not unexpected.
The proposed concept of using ProC Global for screening for thrombophilia due to defects in the protein C system is based on an initial screening with ProC Global, followed by testing for FV Leiden, protein C, and protein S in case of an abnormal screening result. In this study, a cutoff of 0.8 NR was applied for calculation of negative and positive predictive values in the patient panels tested. From the data shown in Table 1 , a negative predictive value of 90% and a positive predictive value of 58% were obtained. However, the low positive predictive value might be a result of defects within the protein C system not yet known today. In fact, if this assay had been evaluated before APC resistance was described by Dahlbäck in 1993, all FV Leiden-positive samples would have been classified as false positive with regard to a protein C pathway defect. Therefore, for estimation of specificity it is better to consider a panel of individuals not affected by thrombophilia (e.g., blood donors). In addition to the significantly differing median NRs observed between healthy donors and thrombophilia patients w ithout FV Leiden, protein C, or protein S deficiency (PWD), the difference becomes obvious in the ROC curve analysis either with the PWD group or the healthy donor group as negative control group (Fig. 3) . Whereas in the first case an area under the curve (AUC) of 0.83 and a specificity 62% for a cutoff of 0.8 NR will result, in the second case a nearly perfect separation of both groups is reflected by an AUC of 0.98 and a specificity of 95%.
Discussion
The relevance of any disturbance within the anticoagulant system for the pathogenesis of venous thromboembolic Significance: * P Ͻ0.05, ** P Ͻ0.01, *** P Ͻ0.001.
Fig. 2. ProC Global in thrombophilic patients.
Clinical Chemistry 43, No. 9, 1997 disease has received increasing acknowledgment within the last several years. Among all defects currently known, defects interfering with the protein C anticoagulant pathway are recognized as the most common abnormality observed, along with a high rate of manifestation. A comparable high manifestation rate is only observed for antithrombin III deficiency, which is rare, being responsible for only ϳ1% of hereditary thrombophilia. Defects within the protein C system can be detected in 25-50% of hereditary thrombophilia [1] . Furthermore, acquired deficiencies of protein C and (or) protein S, as well as lupus anticoagulants interfering with the protein C system, can induce a thrombophilic state. A routine-suited screening assay that would allow the monitoring of the proper interplay of all factors interacting in the protein C pathway could therefore add an important factor to the basic coagulation profile. This consists of PT and APTT, which currently allow only a screening for increased risk for bleeding but not for thromboembolism. In fact, in clinical practice thromboembolic complications are much more frequent than bleeding disorders. ProC Global represents an easy-to-perform screening test that is highly sensitive for FV Leiden and protein C deficiency. The assay is also sensitive to protein S deficiency; in this context one must consider that protein S acts only as a weak accelerator of the protein C system, at least in vitro. Clinical studies have clearly shown the relevance of hereditary protein S deficiency for the development of thromboembolism [1, 4] . In contrast, up to now no study could link low protein S activity or concentration without a hereditary genetic defect to an increased risk for thromboembolism. However, the only published population-based, case-control study could not support an association between protein S deficiency and venous thrombosis because the prevalence of thrombotic disease in individuals with repeatedly low concentrations of protein S did not differ between cases and controls [8] . As hereditary protein S deficiency is rather rare in comparison with the frequently observed acquired deficiency states for protein S activity, the vast majority of the samples showing low protein S activity in this study are expected to represent an acquired, transitional deficiency state and not a genetic defect. Family analysis or follow-up samples were not available from any patient.
In thrombophilic patients, in whom none of the defects of the protein C pathway known up today could be recognized, ProC Global showed significantly lower results than in healthy donors. It may be that the reason for this observation could be the existence of further defects that have not been discovered yet. But also, an increased activity of the procoagulant system could be discussed in this context. For example, high fibrinogen concentrations (Ͼ5 g/L) are connected with a fourfold increased relative risk of thromboembolic disease [9] . Similarly, raised concentrations of FVIII are also associated with thromboembolic disease [10] . Both factors, fibrinogen and FVIII, tested in some samples of this study, were increased above the reference range for most samples measured. However, there were not enough results available to prove the influence of these factors by statistical analysis. Nevertheless, increased fibrinogen and FVIII concentrations may explain at least some of the difference observed between patients without defects and healthy donors. Recently initiated prospective studies will further investigate such influences as well as the predictive value of ProC Global for occurrence of future venous thrombotic complications.
To summarize the results of the present study, the ProC Global assay was highly sensitive for FV Leiden, highly sensitive for protein C activity Ͻ70%, and quite sensitive for protein S activity Ͻ60%. Because the assay is easy to perform and can be applied on automated analyzers, it is suitable for the routine laboratory. The global activity of the protein C anticoagulant pathway in relation to the intrinsic procoagulant system is reflected in a quantitative measure as seen with the ProC Global assay. Because of the high negative predictive value we recommend ProC Global for screening of thrombophilic patients. Further determination of FV Leiden, protein C, and protein S activity is only indicated in case of an abnormal ProC Global result. 
